DEA Corrects Official Chemical Name for Schedule I Controlled Substance Bromazolam

What this means for your practice

This correcting amendment by the DEA, while seemingly minor, underscores the critical importance of precise regulatory language in controlled substance scheduling. For healthcare businesses, including telehealth brands, medspas, dental practices, and chiropractic offices, understanding the exact chemical definitions of controlled substances is paramount for maintaining compliance. Even though Schedule I substances like bromazolam have no accepted medical use and are not legitimately prescribed, practitioners must remain aware of their status. This knowledge is essential for purposes such as identifying illicit substances, understanding the scope of federal drug laws, and ensuring that no unauthorized handling or distribution occurs within their operational sphere. Any engagement, even inadvertent, with substances on Schedule I can lead to severe federal penalties. This action reinforces the DEA's proactive approach to regulating novel psychoactive substances and the necessity for healthcare providers to stay continuously informed about changes to controlled substance schedules.

WASHINGTON, D.C. — The Drug Enforcement Administration (DEA) has issued a correcting amendment to precisely identify the chemical name for bromazolam, a substance previously placed in Schedule I of the Controlled Substances Act. This administrative action, effective June 24, 2026, and applicable beginning March 16, 2026, aims to rectify an earlier error in the chemical nomenclature while affirming bromazolam's continued classification as a Schedule I controlled substance.

Background on Bromazolam's Scheduling

On March 16, 2026, the DEA exercised its authority under the Controlled Substances Act (CSA) to temporarily place 8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine, commonly known as bromazolam, into Schedule I. This temporary order included its salts, isomers, and salts of isomers, whenever such variations are possible. The decision to temporarily schedule bromazolam reflected the DEA's assessment of its potential for abuse and lack of accepted medical use, aligning it with other dangerous drugs with similar profiles.

Following the initial publication, the DEA identified an invalid chemical name for bromazolam in the temporary scheduling order. The agency promptly moved to correct this inaccuracy to ensure the legal and scientific precision of its regulations.

The Nature of the Correcting Amendment

The correcting amendment, published in the Federal Register, specifically addresses and rectifies the invalid chemical name previously associated with bromazolam. The corrected chemical name for bromazolam is now accurately stated as 8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine. This revision affects 21 CFR part 1308, specifically revising paragraph (h)(86) to reflect the accurate chemical identification.

It is crucial to note that this amendment is purely a technical correction to the substance's chemical name. It does not alter bromazolam's status as a Schedule I controlled substance; that classification remains unchanged and was effective as of March 16, 2026.

Implications of Schedule I Classification

Under federal law, Schedule I controlled substances are defined as drugs with:

• A high potential for abuse.
• No currently accepted medical use in treatment in the United States.
• A lack of accepted safety for use under medical supervision.

Examples of other substances in Schedule I include heroin, lysergic acid diethylamide (LSD), cannabis (marijuana), methylenedioxymethamphetamine (ecstasy), and methaqualone. The classification of bromazolam into Schedule I signifies that, from a federal regulatory standpoint, it has no legitimate medical application and presents a significant risk for abuse. Consequently, the manufacture, distribution, possession, and use of bromazolam are subject to stringent federal criminal penalties, except for authorized research purposes.

Why Accuracy in Chemical Nomenclature Matters

The DEA's commitment to correcting the chemical name, even for a temporarily scheduled substance, highlights the importance of precise identification in drug control. Accurate chemical nomenclature is vital for:

• Enforcement: Ensuring law enforcement agencies can correctly identify and prosecute violations involving the substance.
• Laboratory Analysis: Providing unambiguous standards for forensic and research laboratories.
• Regulatory Clarity: Preventing confusion among healthcare providers, researchers, and the public regarding the specific substances subject to control.
• Compliance: Helping regulated entities understand exactly which substances fall under federal control, even if they are not legitimate pharmaceuticals.

This correcting amendment reflects the DEA's continuous efforts to maintain the integrity and accuracy of the Controlled Substances Act and its implementing regulations.

For further information regarding this correction or other inquiries related to drug and chemical evaluation, the DEA encourages direct contact with its Diversion Control Division.

Key Facts

| Detail | Value | |---|---| | Agency | Drug Enforcement Administration (DEA), Department of Justice | | Action | Correcting amendment to 21 CFR Part 1308 | | Substance Corrected | Bromazolam (8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine) | | Scheduling Status | Schedule I of the Controlled Substances Act | | Effective Date of Correction | June 24, 2026 | | Applicable Date of Schedule I Placement | March 16, 2026 |

Frequently Asked Questions

What is bromazolam?

Bromazolam, formally known as 8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine, is a substance that has been placed in Schedule I of the Controlled Substances Act by the DEA due to its high potential for abuse and lack of accepted medical use.

What does being a Schedule I substance mean?

Schedule I substances are federally classified as having a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. They are subject to the strictest controls and are generally unlawful to manufacture, distribute, or possess without specific authorization for research.

Why did the DEA issue this correcting amendment?

The DEA issued this amendment to correct an invalid chemical name for bromazolam that was inadvertently included in the original temporary scheduling order published on March 16, 2026. The correction ensures the accurate identification of the substance.

Does this correction change bromazolam's Schedule I status?

No, this correction only amends the chemical name. Bromazolam remains a Schedule I controlled substance, and its placement in Schedule I was effective on March 16, 2026, as previously announced by the DEA.

Source: DEA — Rule: Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction · 2026-06-24